{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:15:39Z","timestamp":1788869739103,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":77,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2025-00520546"],"award-info":[{"award-number":["RS-2025-00520546"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013129","name":"Ministry of SMEs and Startups","doi-asserted-by":"publisher","award":["RS-2024-00508913"],"award-info":[{"award-number":["RS-2024-00508913"]}],"id":[{"id":"10.13039\/501100013129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"DOI":"10.1186\/s40644-026-01073-1","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:14:10Z","timestamp":1782209650000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The feasibility of [18F]PSMA-1007 PET\/CT for response assessment in prostate cancer following neoadjuvant androgen deprivation therapy compared with mpMRI"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3840-7725","authenticated-orcid":false,"given":"Sangwoo","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3133-2177","authenticated-orcid":false,"given":"Hyo Jung","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9890-6805","authenticated-orcid":false,"given":"Hyunkyung","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1982-2605","authenticated-orcid":false,"given":"Sangwon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7574-6734","authenticated-orcid":false,"given":"Tae Joo","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4438-8890","authenticated-orcid":false,"given":"Young Taik","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8701-4282","authenticated-orcid":false,"given":"Minsun","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1712-163X","authenticated-orcid":false,"given":"Mijin","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"1073_CR1","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.eururo.2024.11.013","volume":"87","author":"EJ Schafer","year":"2025","unstructured":"Schafer EJ, Laversanne M, Sung H, Soerjomataram I, Briganti A, Dahut W, et al. Recent Patterns and Trends in Global Prostate Cancer Incidence and Mortality: An Update. Eur Urol. 2025;87:302\u201313. https:\/\/doi.org\/10.1016\/j.eururo.2024.11.013.","journal-title":"Eur Urol"},{"key":"1073_CR2","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1245\/s10434-018-7035-z","volume":"26","author":"TR McClintock","year":"2019","unstructured":"McClintock TR, von Landenberg N, Cole AP, Lipsitz SR, Gild P, Sun M, et al. Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status. Ann Surg Oncol. 2019;26:297\u2013305. https:\/\/doi.org\/10.1245\/s10434-018-7035-z.","journal-title":"Ann Surg Oncol"},{"key":"1073_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ctrv.2008.08.002","volume":"35","author":"MD Shelley","year":"2009","unstructured":"Shelley MD, Kumar S, Wilt T, Staffurth J, Coles B, Mason MD. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev. 2009;35:9\u201317. https:\/\/doi.org\/10.1016\/j.ctrv.2008.08.002.","journal-title":"Cancer Treat Rev"},{"key":"1073_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/JU.0000000000002757","volume":"208","author":"JA Eastham","year":"2022","unstructured":"Eastham JA, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW, et al. Clinically Localized Prostate Cancer: AUA\/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management. J Urol. 2022;208:10\u20138. https:\/\/doi.org\/10.1097\/JU.0000000000002757.","journal-title":"J Urol"},{"key":"1073_CR5","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1158\/1078-0432.CCR-16-1357","volume":"23","author":"B Montgomery","year":"2017","unstructured":"Montgomery B, Tretiakova MS, Joshua AM, Gleave ME, Fleshner N, Bubley GJ, et al. Neoadjuvant Enzalutamide Prior to Prostatectomy. Clin Cancer Res. 2017;23:2169\u201376. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1357.","journal-title":"Clin Cancer Res"},{"key":"1073_CR6","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s00261-016-0975-5","volume":"42","author":"DT Oberlin","year":"2017","unstructured":"Oberlin DT, Casalino DD, Miller FH, Meeks JJ. Dramatic increase in the utilization of multiparametric magnetic resonance imaging for detection and management of prostate cancer. Abdom Radiol (NY). 2017;42:1255\u20138. https:\/\/doi.org\/10.1007\/s00261-016-0975-5.","journal-title":"Abdom Radiol (NY)"},{"key":"1073_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.02.033","author":"B Turkbey","year":"2019","unstructured":"Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol. 2019;76(3):340\u201351. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.033."},{"key":"1073_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.phro.2021.01.004","volume":"17","author":"U Bjoreland","year":"2021","unstructured":"Bjoreland U, Nyholm T, Jonsson J, Skorpil M, Blomqvist L, Strandberg S, et al. Impact of neoadjuvant androgen deprivation therapy on magnetic resonance imaging features in prostate cancer before radiotherapy. Phys Imaging Radiat Oncol. 2021;17:117\u201323. https:\/\/doi.org\/10.1016\/j.phro.2021.01.004.","journal-title":"Phys Imaging Radiat Oncol"},{"key":"1073_CR9","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1148\/radiology.218.2.r01ja04365","volume":"218","author":"AR Padhani","year":"2001","unstructured":"Padhani AR, MacVicar AD, Gapinski CJ, Dearnaley DP, Parker GJ, Suckling J, et al. Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with mr imaging. Radiology. 2001;218:365\u201374. https:\/\/doi.org\/10.1148\/radiology.218.2.r01ja04365.","journal-title":"Radiology"},{"key":"1073_CR10","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.2967\/jnumed.116.186767","volume":"58","author":"M Eiber","year":"2017","unstructured":"Eiber M, Fendler WP, Rowe SP, Calais J, Hofman MS, Maurer T, et al. Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy. J Nucl Med. 2017;58:S67\u201376. https:\/\/doi.org\/10.2967\/jnumed.116.186767.","journal-title":"J Nucl Med"},{"key":"1073_CR11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2967\/jnumed.125.269818","volume":"67","author":"K Rahbar","year":"2026","unstructured":"Rahbar K, Giesel FL, Herrmann K, Yun M, Watabe T, Rudolph I, et al. Efficacy of [(18)F]PSMA-1007 PET\/CT in Primary Staging of Prostate Carcinoma: A Systematic Review and Metaanalysis. J Nucl Med. 2026;67:85\u201391. https:\/\/doi.org\/10.2967\/jnumed.125.269818.","journal-title":"J Nucl Med"},{"key":"1073_CR12","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.2967\/jnumed.121.263448","volume":"63","author":"L Emmett","year":"2022","unstructured":"Emmett L, Papa N, Buteau J, Ho B, Liu V, Roberts M, et al. The PRIMARY Score: Using Intraprostatic (68)Ga-PSMA PET\/CT Patterns to Optimize Prostate Cancer Diagnosis. J Nucl Med. 2022;63:1644\u201350. https:\/\/doi.org\/10.2967\/jnumed.121.263448.","journal-title":"J Nucl Med"},{"key":"1073_CR13","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.euf.2023.02.001","volume":"9","author":"B Esen","year":"2023","unstructured":"Esen B, Herrmann K, Bavbek S, Kordan Y, Tilki D, Esen T. Prostate-specific Membrane Antigen Positron Emission Tomography as a Biomarker to Assess Treatment Response in Patients with Advanced Prostate Cancer. Eur Urol Focus. 2023;9:596\u2013605. https:\/\/doi.org\/10.1016\/j.euf.2023.02.001.","journal-title":"Eur Urol Focus"},{"key":"1073_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00259-019-04529-8","volume":"47","author":"S Vaz","year":"2020","unstructured":"Vaz S, Hadaschik B, Gabriel M, Herrmann K, Eiber M, Costa D. Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients. Eur J Nucl Med Mol Imaging. 2020;47:9\u201315. https:\/\/doi.org\/10.1007\/s00259-019-04529-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1073_CR15","doi-asserted-by":"publisher","unstructured":"Jena R, Chaudhari P, Gee JC. FireANTs: adaptive Riemannian optimization for multi-scale diffeomorphic matching. arXiv [Preprint]. 2024 Apr 1:arXiv:2404.01249. https:\/\/doi.org\/10.48550\/arXiv.2404.01249.","DOI":"10.48550\/arXiv.2404.01249"},{"key":"1073_CR16","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1097\/00000478-200310000-00001","volume":"27","author":"ME Chen","year":"2003","unstructured":"Chen ME, Johnston D, Reyes AO, Soto CP, Babaian RJ, Troncoso P. A streamlined three-dimensional volume estimation method accurately classifies prostate tumors by volume. Am J Surg Pathol. 2003;27:1291\u2013301. https:\/\/doi.org\/10.1097\/00000478-200310000-00001.","journal-title":"Am J Surg Pathol"},{"key":"1073_CR17","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.radonc.2019.07.002","volume":"141","author":"C Zamboglou","year":"2019","unstructured":"Zamboglou C, Fassbender TF, Steffan L, Schiller F, Fechter T, Carles M, et al. Validation of different PSMA-PET\/CT-based contouring techniques for intraprostatic tumor definition using histopathology as standard of reference. Radiother Oncol. 2019;141:208\u201313. https:\/\/doi.org\/10.1016\/j.radonc.2019.07.002.","journal-title":"Radiother Oncol"},{"key":"1073_CR18","doi-asserted-by":"publisher","first-page":"897700","DOI":"10.3389\/fonc.2022.897700","volume":"12","author":"YC Lau","year":"2022","unstructured":"Lau YC, Chen S, Ho CL, Cai J. Reliability of gradient-based segmentation for measuring metabolic parameters influenced by uptake time on 18F-PSMA-1007 PET\/CT for prostate cancer. Front Oncol. 2022;12:897700. https:\/\/doi.org\/10.3389\/fonc.2022.897700.","journal-title":"Front Oncol"},{"key":"1073_CR19","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.neuroimage.2006.01.015","volume":"31","author":"PA Yushkevich","year":"2006","unstructured":"Yushkevich PA, Piven J, Hazlett HC, Smith RG, Ho S, Gee JC, et al. User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. NeuroImage. 2006;31:1116\u201328. https:\/\/doi.org\/10.1016\/j.neuroimage.2006.01.015.","journal-title":"NeuroImage"},{"key":"1073_CR20","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/mrm.23062","volume":"67","author":"T Barrett","year":"2012","unstructured":"Barrett T, Gill AB, Kataoka MY, Priest AN, Joubert I, McLean MA, et al. DCE and DW MRI in monitoring response to androgen deprivation therapy in patients with prostate cancer: a feasibility study. Magn Reson Med. 2012;67:778\u201385. https:\/\/doi.org\/10.1002\/mrm.23062.","journal-title":"Magn Reson Med"},{"key":"1073_CR21","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.ijrobp.2010.02.060","volume":"80","author":"R Alonzi","year":"2011","unstructured":"Alonzi R, Padhani AR, Taylor NJ, Collins DJ, D\u2019Arcy JA, Stirling JJ, et al. Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: an in vivo human study using susceptibility and relaxivity dynamic MRI. Int J Radiat Oncol Biol Phys. 2011;80:721\u20137. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.02.060.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1073_CR22","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.acra.2019.10.017","volume":"27","author":"FM Fennessy","year":"2020","unstructured":"Fennessy FM, Fedorov A, Vangel MG, Mulkern RV, Tretiakova M, Lis RT, et al. Multiparametric MRI as a Biomarker of Response to Neoadjuvant Therapy for Localized Prostate Cancer-A Pilot Study. Acad Radiol. 2020;27:1432\u20139. https:\/\/doi.org\/10.1016\/j.acra.2019.10.017.","journal-title":"Acad Radiol"},{"key":"1073_CR23","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1007\/s00330-015-3688-1","volume":"25","author":"AM Hotker","year":"2015","unstructured":"Hotker AM, Mazaheri Y, Zheng J, Moskowitz CS, Berkowitz J, Lantos JE, et al. Prostate Cancer: assessing the effects of androgen-deprivation therapy using quantitative diffusion-weighted and dynamic contrast-enhanced MRI. Eur Radiol. 2015;25:2665\u201372. https:\/\/doi.org\/10.1007\/s00330-015-3688-1.","journal-title":"Eur Radiol"},{"key":"1073_CR24","doi-asserted-by":"publisher","first-page":"W645","DOI":"10.2214\/AJR.13.12277","volume":"203","author":"AY Kim","year":"2014","unstructured":"Kim AY, Kim CK, Park SY, Park BK. Diffusion-weighted imaging to evaluate for changes from androgen deprivation therapy in prostate cancer. AJR Am J Roentgenol. 2014;203:W645\u201350. https:\/\/doi.org\/10.2214\/AJR.13.12277.","journal-title":"AJR Am J Roentgenol"},{"key":"1073_CR25","doi-asserted-by":"publisher","first-page":"e35225","DOI":"10.1016\/j.urolonc.2019.01.012","volume":"37","author":"SA Gold","year":"2019","unstructured":"Gold SA, VanderWeele DJ, Harmon S, Bloom JB, Karzai F, Hale GR, et al. mpMRI preoperative staging in men treated with antiandrogen and androgen deprivation therapy before robotic prostatectomy. Urol Oncol. 2019;37:e35225\u201330. https:\/\/doi.org\/10.1016\/j.urolonc.2019.01.012.","journal-title":"Urol Oncol"},{"key":"1073_CR26","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1158\/1078-0432.CCR-20-2344","volume":"27","author":"F Karzai","year":"2021","unstructured":"Karzai F, Walker SM, Wilkinson S, Madan RA, Shih JH, Merino MJ, et al. Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response. Clin Cancer Res. 2021;27:429\u201337. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2344.","journal-title":"Clin Cancer Res"},{"key":"1073_CR27","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1093\/hmg\/10.23.2637","volume":"10","author":"L Liu","year":"2001","unstructured":"Liu L, Done SC, Khoshnoodi J, Bertorello A, Wartiovaara J, Berggren PO, et al. Defective nephrin trafficking caused by missense mutations in the NPHS1 gene: insight into the mechanisms of congenital nephrotic syndrome. Hum Mol Genet. 2001;10:2637\u201344. https:\/\/doi.org\/10.1093\/hmg\/10.23.2637.","journal-title":"Hum Mol Genet"},{"key":"1073_CR28","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1007\/s00259-018-4079-z","volume":"45","author":"A Afshar-Oromieh","year":"2018","unstructured":"Afshar-Oromieh A, Debus N, Uhrig M, Hope TA, Evans MJ, Holland-Letz T, et al. Impact of long-term androgen deprivation therapy on PSMA ligand PET\/CT in patients with castration-sensitive prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:2045\u201354. https:\/\/doi.org\/10.1007\/s00259-018-4079-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1073_CR29","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.1007\/s00259-023-06321-1","volume":"50","author":"C Onal","year":"2023","unstructured":"Onal C, Guler OC, Torun N, Oymak E, Reyhan M. The significance of metabolic response to neoadjuvant androgen deprivation therapy detected with [(68)Ga]Ga-PSMA-11-PET\/CT in high-risk prostate cancer patients treated with definitive radiotherapy. Eur J Nucl Med Mol Imaging. 2023;50:3755\u201364. https:\/\/doi.org\/10.1007\/s00259-023-06321-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1073_CR30","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1007\/s00259-019-04581-4","volume":"47","author":"C Onal","year":"2020","unstructured":"Onal C, Guler OC, Torun N, Reyhan M, Yapar AF. The effect of androgen deprivation therapy on (68)Ga-PSMA tracer uptake in non-metastatic prostate cancer patients. Eur J Nucl Med Mol Imaging. 2020;47:632\u201341. https:\/\/doi.org\/10.1007\/s00259-019-04581-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1073_CR31","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00259-019-04635-7","volume":"47","author":"O Ettala","year":"2020","unstructured":"Ettala O, Malaspina S, Tuokkola T, Luoto P, Loyttyniemi E, Bostrom PJ, et al. Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with (68)Ga-PSMA-11 PET\/MRI in men with treatment-naive prostate cancer. Eur J Nucl Med Mol Imaging. 2020;47:665\u201373. https:\/\/doi.org\/10.1007\/s00259-019-04635-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1073_CR32","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.2967\/jnumed.123.265874","volume":"64","author":"QA Shagera","year":"2023","unstructured":"Shagera QA, Karfis I, Kristanto P, Spyridon S, Diamand R, Santapau A, et al. PSMA PET\/CT for Response Assessment and Overall Survival Prediction in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors. J Nucl Med. 2023;64:1869\u201375. https:\/\/doi.org\/10.2967\/jnumed.123.265874.","journal-title":"J Nucl Med"},{"key":"1073_CR33","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.2214\/AJR.13.11456","volume":"202","author":"P Sridhar","year":"2014","unstructured":"Sridhar P, Mercier G, Tan J, Truong MT, Daly B, Subramaniam RM. FDG PET metabolic tumor volume segmentation and pathologic volume of primary human solid tumors. AJR Am J Roentgenol. 2014;202:1114\u20139. https:\/\/doi.org\/10.2214\/AJR.13.11456.","journal-title":"AJR Am J Roentgenol"},{"key":"1073_CR34","doi-asserted-by":"publisher","first-page":"8396","DOI":"10.7150\/thno.58140","volume":"11","author":"J Jiao","year":"2021","unstructured":"Jiao J, Kang F, Zhang J, Quan Z, Wen W, Zhao X, et al. Establishment and prospective validation of an SUV(max) cutoff value to discriminate clinically significant prostate cancer from benign prostate diseases in patients with suspected prostate cancer by (68)Ga-PSMA PET\/CT: a real-world study. Theranostics. 2021;11:8396\u2013411. https:\/\/doi.org\/10.7150\/thno.58140.","journal-title":"Theranostics"},{"key":"1073_CR35","doi-asserted-by":"publisher","first-page":"935","DOI":"10.4155\/cli.14.77","volume":"4","author":"K Izumi","year":"2014","unstructured":"Izumi K, Li L, Chang C. Androgen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer. Clin Investig (Lond). 2014;4:935\u201350. https:\/\/doi.org\/10.4155\/cli.14.77.","journal-title":"Clin Investig (Lond)"},{"key":"1073_CR36","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1016\/j.ajpath.2013.02.028","volume":"182","author":"K Izumi","year":"2013","unstructured":"Izumi K, Mizokami A, Lin WJ, Lai KP, Chang C. Androgen receptor roles in the development of benign prostate hyperplasia. Am J Pathol. 2013;182:1942\u20139. https:\/\/doi.org\/10.1016\/j.ajpath.2013.02.028.","journal-title":"Am J Pathol"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-026-01073-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01073-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01073-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:03:40Z","timestamp":1788869020000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40644-026-01073-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1073"],"URL":"https:\/\/doi.org\/10.1186\/s40644-026-01073-1","relation":{"references":[{"id-type":"doi","id":"10.1016\/j.eururo.2019.02.033","asserted-by":"subject"}]},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"8 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. The present study protocol was reviewed and approved by the institutional review board of Severance Hospital (IRB No. [4-2025-0483]), and the requirement for informed consent was waived due to the retrospective nature of the study.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mijin Yun is the CEO of Newcure M inc., a company that distributes [\n                      18\n                      F] PSMA-1007. However, the radiotracers in this study were administered as part of routine clinical practice, and the study was conducted retrospectively. Newcure M inc. had no role in the study design, data collection, analysis, interpretation, manuscript preparation, or decision to publish. All other authors have no relevant financial or nonfinancial interests to disclose.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"121"}}